Squarepoint
AQST icon

Squarepoint’s Aquestive Therapeutics AQST Stock Holding History

Squarepoint’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-81,000
Closed -$345K – 4026
2024
Q1 		$345K Buy
+81,000
New +$270K ﹤0.01% 3298

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Squarepoint's AQST Position: Q1 2026 in Review

Squarepoint opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 249,482 shares worth $1.04M. The stake represents ﹤0.01% of the portfolio and ranks #2754 among its holdings. This is a return to the name: Squarepoint previously reported a position in AQST as recently as Q2 2025.

Squarepoint first reported a position in AQST in Q4 2018 and has held it in 17 quarters since. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Squarepoint held 249,482 shares of Aquestive Therapeutics worth $1.04M as of Q1 2026.
  • Aquestive Therapeutics was a new Squarepoint position in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2754 holding.
  • Squarepoint first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.